Ask AI
ProCE Banner Activity

MK-8527 PrEP: Phase I-II PK Analysis to Inform Dosing for EXPrESSIVE Phase III Trial Program

Conference Coverage
Slideset

A pharmacokinetics analysis using data from phase I and II trials suggests that once-monthly MK-8527 at 11 mg should be efficacious and safe for preventing HIV infection, including in special populations. This will be used for phase III development in the ongoing EXPrESSIVE program.

Released: February 27, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions